The Foods & Oil to Repair, Correct and Enhance Strength (FORCES) Study

April 11, 2024 updated by: Martha Belury, Ohio State University

The Foods & Oil to Repair, Correct and Enhance Strength (FORCES) Study: Determining the Effect of Dietary Oils on Muscle Function, Strength and Mass

The proposed research is a parallel arm, randomized placebo-controlled clinical trial designed to assess changes in muscle strength, volume, fatigue resistance, and mobility in older adults after daily consumption of 12g of linoleic acid-rich oil.

Study Overview

Status

Not yet recruiting

Conditions

Detailed Description

Study Objectives

  1. To assess the effect of linoleic acid supplementation on muscle strength, muscle volume, fatigue- resistance, and physical mobility.
  2. To quantify the impact of linoleic acid supplementation on cardiolipin species and mitochondrial function in skeletal muscle of older adults

Study Type

Interventional

Enrollment (Estimated)

66

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

  • Name: Martha Belury, PhD RDN
  • Phone Number: 614-292-1680
  • Email: belury.1@osu.edu

Study Contact Backup

Study Locations

    • Ohio
      • Columbus, Ohio, United States, 43210
        • The Ohio State University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Linoleic Acid Intake <75% of the adequate intake
  • Probable sarcopenia

Exclusion Criteria:

  • Gastrointestinal diseases or disorders (including pancreatic and gastric bypass surgery) where consumption of the study foods would be contraindication or where the disease or disorder could negatively affect nutrient absorption and/or would prevent participants from tolerating the study foods
  • Hyperthyroidism diagnosis
  • Food Allergy or intolerances
  • Any dietary restriction where consumption of the study foods or any ingredient would be contraindicated
  • Unstable management of heart failure, heart disease events (including stroke or heart attack) within last 3 months prior to enrollment, a plan for heart surgeries or cardiac procedures
  • Current or previous diagnosis of severe kidney failure, liver cirrhosis, other liver diseases/infections that cause liver damage and some pulmonary diseases or severe/uncontrolled pulmonary diseases
  • Severe or uncontrolled rheumatologic or orthopedic diseases
  • Current diagnosis of or current treatment of cancer other than non-melanoma skin cancer
  • Neuromuscular or neurological conditions or diseases or use of mobility assistance (wheelchair, walker etc..) that would impact movement needed to perform the muscle function tests or prevent completion of the muscle function tests
  • Use of mobility assistance (wheelchair, walker etc..) that would prevent completion of the muscle function tests
  • Current use of supplements or medications for weight loss or following a weight loss program
  • Use of supplements high in linoleic acid in the past 4 weeks prior to enrolling
  • Pregnancy and lactation
  • Alcohol or drug abuse
  • Allergy/intolerance to lidocaine or similar medication
  • Use of anticoagulant, antiplatelet, or other blood thinner medications
  • Terminal Illness
  • Any condition leading to muscle loss or weakness, impaired mobility or range of motion in legs (excluding normal aging)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Quadruple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: High Linoleic Safflower Oil
consumption of 12g of high linoleic safflower oil every day
Two food products containing 6g of high linoleic safflower oil each will be consumed each day for a total of 12g daily
Placebo Comparator: High Oleic Safflower Oil
Consumption of 12g of high oleic safflower oil every day
Two food products containing 6g of high oleic safflower oil each will be consumed each day for a total of 12g daily

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Changes is leg extensor muscle strength
Time Frame: Week 0 and Week 24
To determine the impact of high linoleic safflower oil on isokinetic leg extensor muscle strength through isokinetic dynamometer
Week 0 and Week 24

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Changes in quadriceps muscle volume
Time Frame: Week 0 and Week 24
To determine the impact of high linoleic safflower oil on quadriceps muscle volume through MRI
Week 0 and Week 24
Change in maximum leg press strength
Time Frame: Week 0 and Week 24
To determine the impact of high linoleic safflower oil on maximum leg press strength using leg press machine
Week 0 and Week 24
Change in leg fatiguability
Time Frame: Week 0 and Week 24
To determine the impact of high linoleic safflower oil on muscle fatiguability through isokinetic dynamometer
Week 0 and Week 24
Change in muscle mitochondria function
Time Frame: Week 0 and Week 24
To determine the impact of high linoleic safflower oil on muscle and peripheral blood mononuclear cell mitochondria oxygen consumption rate using the Oroboros instrument
Week 0 and Week 24
Changes in cardiolipin species
Time Frame: Week 0 and Week 24
To determine the impact of high linoleic safflower oil on muscle and peripheral blood mononuclear cell cardiolipin species measured using electrospray ionization-mass spectrometry coupled to high-performance liquid chromatography.
Week 0 and Week 24
Changes in grip strength
Time Frame: Week 0 and Week 24
To determine the impact of high linoleic safflower oil on grip strength measured using hand dynamometer.
Week 0 and Week 24
Changes in gait speed
Time Frame: Week 0 and Week 24
To determine the impact of high linoleic safflower oil on gait speed measured by timing a 400-meter walk.
Week 0 and Week 24
Changes in chair rise time
Time Frame: Week 0 and Week 24
To determine the impact of high linoleic safflower oil on chair rise time measured by timing rise from a seated position five times.
Week 0 and Week 24
Changes in stair climb power
Time Frame: Week 0 and Week 24
To determine the impact of high linoleic safflower oil on stair climb time measured by timing the completion of climbing 1 flight of stairs
Week 0 and Week 24
Change in short physical performance battery score
Time Frame: Week 0 and Week 24
To determine the impact of high linoleic safflower oil on short physical performance battery short score which is calculated by measured by measuring time it takes to walk 4 meters, rise from a chair 5 times and the ability to balance in 3 standing positions for 10 seconds each. Scores range from 0 (predicts for worst physical performance) to 12 (predicts for best physical performance)
Week 0 and Week 24
change in blood fatty acids
Time Frame: Week 0 and Week 24
To determine the impact of high linoleic safflower oil on changes in blood fatty acids using gas chromatography
Week 0 and Week 24

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Association of changes in plasma linoleic acid with muscle function
Time Frame: Week 0 and Week 24
Use multiple linear regressions to determine the association of change in plasma linoleic acid with changes in leg extensor muscle strength
Week 0 and Week 24
Association of changes in plasma linoleic acid with muscle strength
Time Frame: Week 0 and Week 24
Use multiple linear regressions to determine the association of change in plasma linoleic acid with changes in maximum leg press strength
Week 0 and Week 24
Association of changes in plasma linoleic acid with muscle volume
Time Frame: Week 0 and Week 24
Use multiple linear regressions to determine the association of change in plasma linoleic acid with changes in muscle volume measured by MRI
Week 0 and Week 24
Association of changes 4-LA-cardiolipin with muscle function
Time Frame: Week 0 and Week 24
Use multiple linear regressions to determine the association of change in 4-LA-cardiolipin with changes in leg extensor muscle strength
Week 0 and Week 24
Association of changes 4-LA-cardiolipin with muscle strength
Time Frame: Week 0 and Week 24
Use multiple linear regressions to determine the association of change in 4-LA-cardiolipin with changes in maximum leg press strength.
Week 0 and Week 24
Association of changes 4-LA-cardiolipin with muscle volume
Time Frame: Week 0 and Week 24
Use multiple linear regressions to determine the association of change in 4-LA-cardiolipin with changes in leg muscle volume measured by MRI
Week 0 and Week 24
Association of changes mitochondria function with muscle volume.
Time Frame: Week 0 and Week 24
Use multiple linear regressions to determine the association of change in mitochondria function with changes in leg muscle volume measured by MRI
Week 0 and Week 24
Association of changes mitochondria function with muscle function
Time Frame: Week 0 and Week 24
Use multiple linear regressions to determine the association of change in mitochondria function with changes in leg extensor muscle strength.
Week 0 and Week 24
Association of changes mitochondria function with muscle strength.
Time Frame: Week 0 and Week 24
Use multiple linear regressions to determine the association of change in mitochondria function with changes in maximum leg press strength.
Week 0 and Week 24

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Martha Belury, PhD RDN, Ohio State University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

May 1, 2024

Primary Completion (Estimated)

May 1, 2029

Study Completion (Estimated)

May 1, 2030

Study Registration Dates

First Submitted

April 5, 2024

First Submitted That Met QC Criteria

April 11, 2024

First Posted (Actual)

April 12, 2024

Study Record Updates

Last Update Posted (Actual)

April 12, 2024

Last Update Submitted That Met QC Criteria

April 11, 2024

Last Verified

April 1, 2024

More Information

Terms related to this study

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Sarcopenia

Clinical Trials on High Linoleic Acid Foods

3
Subscribe